Behçet disease with ocular involvement — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Infliximab
Sight-threatening Behçet uveitis and retinal vasculitis require urgent immunosuppression, and anti-TNF monoclonal therapy such as infliximab is an established option. Etanercept is not preferred for ocular Behçet disease. Delay risks irreversible visual loss, so ophthalmology and rheumatology should manage jointly.
Reference: BAD/BSR Behçet disease living guideline 2025; EULAR Behçet recommendations